The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

about

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

Item

http://www.wikidata.org/entity/Q53543459

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@en

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@nl

type

Item

label

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@en

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@nl

prefLabel

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@en

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@nl

P1476

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

@en

P2093

Chloe Stengel-Tosetti

http://www.w3.org/2001/XMLSchema#string

Craig J Gibson

http://www.w3.org/2001/XMLSchema#string

Luis Felipe Casado Montero

http://www.w3.org/2001/XMLSchema#string

Steve Schey

http://www.w3.org/2001/XMLSchema#string

Sujith Dhanasiri

http://www.w3.org/2001/XMLSchema#string

P2860

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.

Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.

Can we change the disease biology of multiple myeloma?

Frontline therapy of multiple myeloma.

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

P2888

s40487-016-0037-8

P304

31-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40487-016-0037-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28680953

http://www.w3.org/2001/XMLSchema#string

P932

5488111

http://www.w3.org/2001/XMLSchema#string